celltrion gsc 2011 ar
TRANSCRIPT
-
7/24/2019 Celltrion GSC 2011 AR
1/165
Annual Report of Celltrion GSC in 2011
1 January 2011 to 31 December 2011
-
7/24/2019 Celltrion GSC 2011 AR
2/165
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
"# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
$# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
%# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7
'# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
(# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
)# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10
""# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11"""# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21
"*# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55
*# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57
*"# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60
$# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60
%# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .62
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .62
'# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .63
*""# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .64
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .65
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .66
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
*"""# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69
$# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
%# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .72"+# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73
+# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75
+"# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77
+""# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .78
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
$# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
%# . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
-
7/24/2019 Celltrion GSC 2011 AR
3/165
3
Content
Annual report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . .4Confirmation of Executives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . .6
I. Company Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71. Company profile. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . .72. Company history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .73. Change in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . .9
Status of outstanding convertible bonds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 11Status of outstanding bonds with warrants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . 13
4. Total number of shares. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 15Status of the total number of shares .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . .. . 15Status of the acquisition and disposal of its own shares. . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 17
5. Status of the voting rights. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 196. Dividend payment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . .21
II. Business Overview. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23
III. Financial Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49
IV. Auditors Opinions.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . .. . . . .. 130
V. Operational diagnosis and Analytic Opinions of the Chief Excecutive Officer. . . . . . . . . . .. . . ..133
VI. Related issues about the Company Departments (i.e. board of directors) and Subsidiaries...1381. Board of Directors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .1382. Supervision system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1413. The voting rights of shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .143
4. Status of subsidiaries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .144
VII. Issues concerning shareholders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145The shareholding status of majority shareholder and related parties . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145Changes in the shareholding of majority shareholder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145Status of shareholding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . .145Minority shareholders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145
VIII. Executives and Staff. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . 1471. Status of executives and staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1472. Remuneration of executives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .148
IX. Transactions with stakeholders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .151
X. Necessary Measures to Protect Other Investors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
XI. Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .159
XII. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . .161
Confirmation of experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1631. Confirmation of experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .1642. The interests of experts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
-
7/24/2019 Celltrion GSC 2011 AR
4/165
4
,$% -
"#$$ #$ #$
"#$$ $" %$
"#$" #%
%#
&
&
& $%'%
( ) *#%"'+(#',-,-
)* .//0&11
& ) * ) *
) *#%"'+(#',-,-
-
7/24/2019 Celltrion GSC 2011 AR
5/165
Page | 5
Annual Report
12thperiod
Financial year: 1 January 2011 to 31 December 2011Company: Celltrion GSC CorporationCEO: Kim Tae-kuHeadquarter location: 13-35thfloor of Songdo-dong, Yeonsu-gu, Incheon (Tel) 032-850-6464Reporting Director: Lee Byeong-lyurTel: 032-850-6464
-
7/24/2019 Celltrion GSC 2011 AR
6/165Page | 6
-
7/24/2019 Celltrion GSC 2011 AR
7/165Page | 7
Executive Confirmation
As executives of the company and the people in charge of the preparation of the financial statements, we havepaid significant attention to the content of the financial statements of this financial year. After directconfirmation and discussions, we confirm that no record or note of major events was omitted and there was nofalse record or note. Therefore, the contents of the report will not lead to major misunderstandings for users.
Moreover, we confirm that the company has set up an internal accounting management system according to thesecond and third paragraph of the second article of The Law Concerning the External Audit of Corporations.Andthe company has operated in compliance with this system.
March 30th2012 Celltrion GSC Corp.
CEO: Kim Tae-ku
Reporting Director: Lee Byeong-lyur
-
7/24/2019 Celltrion GSC 2011 AR
8/165
dart.fss.or.kr Page 4
$#
"#
# #.
# . %///#/)#$'# . $&0&
( . /&% 0 1(/ 0 )')'
# .
# .
$2
"2
%2 3 3 3 3 3
-2
(2 )* 3
,2 3 3
42
+2
'
%#
#
,$-
"##+2#%2%$
"##+2$"2%#
& )* )*
$
"##52#$2$"
"##52#"2#$
"##52#"2"4
"##52#%2$5
"##52#-2#"
$
)(3### * )$$"5'22
4'(#* "
)43### *
) *
"#$#2$$2%# " )" 6(3###*
"#$$2#+2#$ )4'50 $%'%*
,%- 0 %//2 & $2
,-,- #
-
7/24/2019 Celltrion GSC 2011 AR
9/165
I Company Introduction
Company profile
a) Legal name and business name of the company: Celltrion GSC Corperation
bDate of establishment: 14 June 2000
cHeadquarter location: 13-3 5thfloor of Songdo-dong, Yeonsu-gu, Incheon (tel) 032-850-6464
dScale: small to medium enterpriseeMajor business: business purposes in the Article of Association
Business purposses Remarks
1. Manufacture of excipients for medicine production
2. Research and development for materials localization
3. Trade and trade agency for medicine, pharmaceutical raw materials, chemicals,
medicines for external use, basic compounds and excipients for medicine
production
4. Overall business related to each phase
5. Wholesale of equipment (machinery), parts and accessories
6. Manufacture of pharmaceutical raw materials, chemicals, and basic compounds7. Procurement and logistics consultancy
8. Procurement agency
-
Company history
a) Company history
(1) Changes after company establishment
Time Process and major changes
31 Mar 2008Change of CEO: changed from Seo Jung-jin to Kim Tae-ku
For the first time the company issued unsecured convertible bonds with a value of KRW
5 BN
Jan 12 2009
Feb 1 2009
Feb 27 2009
Mar 19 2009
Apr 2 2009
For the first time the company issued bearer bonds with non-detachable warrants with avalue of KRW 5 BNThe head office was moved from 1129-22 Guwol-dong, Namdong-gu, Incheon to 7-50
Songdo-dong, Yeonsu-gu, Incheon
The company issued unsecured convertible bonds with a value of KRW 7 BN for the
second time
The company name was changed from Nexolbiotech to Celltrion GSC
The company issued unsecured convertible bonds with a value of KRW 5 BN for the thirdtime
Nov 30 2010Equity investment from TOMATO 2 Savings Bank (2 million shares with aprice of KRW5,000 per share)
Aug 1 2011The head office was moved from 7-50 Songdo-dong, Yeonsu-gu, Incheon to 13-3Songdo-dong, Yeonsu-gu, Incheon
(2) The change in company name
The company name was changed from Nexolbiotech toCelltrion GSC through a regular
shareholders meeting on 19 March 2009
-
7/24/2019 Celltrion GSC 2011 AR
10/165
6
,-
)& "#$$ $" %$ * )& 3 *
)*
)*
)*
)*
"###
#,
)* $#3### (3### (3### '
"##$
#-
)* -#3### (3### (3### '
"##$
#-
)* "#3### (3### (3### '
"##$
#5
)* $,3### (3### (3### '
"##$
$#
)* $$-3### (3### (3### '
"##"
#%
) % * +-34## (3### $(53-## '
"##"
#-
"3,#43-+
#
(3### (3### '
"##"
$#
$3$(53+#
#
(3### -3,4, '
-
7/24/2019 Celltrion GSC 2011 AR
11/165
7
# Changes in Capital
Capital increase/decrease(Base date: 31 December 2011) Unit: KRW, per share
Date of Share
Issurance/Decrease
Form of
Issuance/Decrease
Stock Issurance/Decrease
Category Quantity Par Value
per Share
Issurance/
Decrease Price
per Share
Remarks
Jun 22 2000
Capital increase withconsideration (rights
offering)
Commonstock
10,000 5,000 5,000 -
Apr 4 2001
Capital increase withconsideration (rights
offering)
Commonstock 40,000 5,000 5,000 -
Apr 17 2001
Capital increase withconsideration (rights
offering)
Commonstock 20,000 5,000 5,000 -
Slep 25 2001
Capital increase withconsideration (rights
offering)
Commonstock
16,000 5,000 5,000 -
Oct 31 2001
Capital increase withconsideration (rights
offering)
Commonstock 114,000 5,000 5,000 -
Mar 23 2002Capital increase with
consideration (the 3rd
offering)
Common
stock 84,700 5,000 159,400 -
Apr 24 2002Capital increase
without considerationCommon
stock 2,607,480 5,000 5,000 -
Oct 10 2002Capital reduction Common
stock 1,159,800 5,000 4,676 -
-
7/24/2019 Celltrion GSC 2011 AR
12/165
8
)& "#$$ $" %$ * )& 3
*
)7*
$
"##+
$"
%#
"#$"
$"
"5
(3###
"#$#2%2$8
"#$"2$"2"
+
$## %(34(" (3### $%53+(" '
"
"##5
#"
"4
"#$%
#"
",
43###
"#$#2%2$8
"#$%2#"2"
(
$## %43,## 43### $+,3$4# '
%
"##5 #-
#"
"#$% #-
#$
(3###
"#$#2#-2#"8
"#$%2#-2#
$
$## %43,## (3### $%"354+ '
' ' $"3### ' ' ' ' $"3### -(53### '
,3- #
-
7/24/2019 Celltrion GSC 2011 AR
13/165
9
Status of Outstanding Convertible Bonds
Base date: December 31 2011 Unit: KRW MN per share
Class
Date of
Issurance
Date of
Maturity
Total
BookValue
Type of Shares
for Conversion
Period for
Possible
Conversion
Claims
Conversion conditions Outstanding Bonds
RemarksConversion
Rate
ConversionPrice
TotalBookValue
Shares for
Possible
Conversion
First
unsecured
convertible
bonds
Dec 302008
Dec 292012
5,000Registered
conmmon stock
Mar 1 2010~
Dec 28 2012100 35,752 5,000 139,852 -
Secondunsecured
convertible
bonds
Feb 272009
Feb 62013
7,000Registered
common stock
Mar 1 2010~
Feb 25 2013100 37,600 7,000 186,170 -
Third
unsecured
convertible
bonds
Apr 22009
Apr 12013
5,000Registered
common stock
Apr 2 2010~
Apr 1 2013100 37,600 5,000 132,978 -
Total - - 12,000 - - - - 12,000 459,000 -
(*) Bondholders have the full exercise of the stock options
-
7/24/2019 Celltrion GSC 2011 AR
14/165
10
)& "#$$ $" %$ * )& 3
*
)7*
$
"##5
#$
$"
"#$%
#$
$$
(3###
"#$#2#$
2$%8"#
$%2#$2$
#
$## %(34(" (3### $%53+(" '
' ' (3### ' ' ' ' (3### $%53+(" '
,3- #
-
7/24/2019 Celltrion GSC 2011 AR
15/165
11
Status of Outstanding Bonds with Warrants
Base date: Dec 31 2011 Unit: KRW MN per share
ClassDate of
Issue
Date of
Maturity
Total
Book
Value
Type of
Shares
Period for
Possible
Exercise ofOptions
ExerciseConditions
Bonds which
Have Not been
ExercisedRemarks
Exercise
Rate
Exercise
Price
Total
Book
Value
Shares for
Possible
Exercise
First
unregistered
bonds with
detachable
warrants
Jan 122009
Jan 112013
5,000
Registered
common
stock
Jan 13 2010~Jan 10 2013
100 35,752 5,000 139,852 -
Total - - 5,000 - - - - 5,000 139,852 -
(*) Shareholders have the full exercise of the stock options
-
7/24/2019 Celltrion GSC 2011 AR
16/165
12
'#
)& "#$$ $" %$ * )& *
. -3###3### ' -3###3### '
. "3+5"3$+# ' "3+5"3$+# '
. $3$(53+## ' $3$(53+## '
$2 $3$(53+## ' $3$(53+## '
"2 ' ' ' '
%2 ' ' ' '
-2 ' ' ' '
. (') $34%"3%+# ' $34%"3%+# '
. "%% ' "%% '
. (') $34%"3$-4 ' $34%"3$-4 '
-
7/24/2019 Celltrion GSC 2011 AR
17/165
13
$
The total number of shares
Status of Total Number of Shares
Base date: Dec 31 2011 Unit: per share
DivisionType of Share
RemarksCommon Stock Total
. Total number of issued shares 4,000,000 - 4,000,000 -
. Total number of shares issued to date2,892,180 - 2,892,180 -
. Total number of shares which
decreased to date1,159,800 - 1,159,800 -
1. Capital reduction1,159,800 - 1,159,800 -
2. Profit redemption
- - - -3. Repayment of redeemable shares
- - - -
4. Others - - - -
. Total number of outstanding shares1,732,380 - 1,732,380 -
. Self-owned shares 233 - 233 -
. Number of outstanding shares 1,732,147 - 1,732,147 -
-
7/24/2019 Celltrion GSC 2011 AR
18/165
14
)& "#$$ $" %$ * )& *
)9* )'* )'*
' ' ' ' ' ' ' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
):* ' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
' ' ' ' ' '
);* ' ' ' ' ' '
' ' ' ' ' '
)
-
7/24/2019 Celltrion GSC 2011 AR
19/165
15
Status of the acquisition and disposal of own shares
Base date: Dec 31 2011 Unit: per share
Acquistion Method Type of StocksBasic
Quantity
Quantity change Final
QuantityRemark
sAcquisition Disposal Redemption
Legal
acquisitionin capital
market
Direct
acquisition
Acquisitionfromexchange
Common stock - - - - - -
Preferredstock
- - - - - -
Publicpurchase
Common stock - - - - - -
Preferredstock
- - - - - -
Exercise of
share
purchase
rights
Common stock - - - - - -
Preferredstock
- - - - - -
Subtotal
Common stock - - - - - -
Preferredstock
- - - - - -
Acquistion
through
trust
agreement
Quantityheld bytrustees
Common stock - - - - - -
Preferred - - - - - -
Currentholdingquantity
Common stock - - - - - -
Preferredstock
- - - - - -
Subtotal
Common stock - - - - - -
Preferredstock
- - - - - -
Acquisition through other methods
Common stock 233 - - - 233 Note 1
Preferredstock
- - - - - -
Total
Common stock 233 - - - 233 -
Preferredstock
- - - - - -
Note 1: acquired through capital increase without consideration on 24 April 2002
-
7/24/2019 Celltrion GSC 2011 AR
20/165
16
(#
)& "#$$ $" %$ * )& *
)=* $34%"3%+# '
' '
)>* ' '
' '
)?*
"%% '
' '
)@* ' '
' '
)A B = ' > ' ? 9 @*
$34%"3$-4 '
' '
-
7/24/2019 Celltrion GSC 2011 AR
21/165
17
% Status of Voting Rights
Base date: Dec 31 2011 Unit: per share
Division Number of Shares Remarks
Total number of issued shares (A)Common stock 1,732,380 -
Preferred stock - -
Number of shares without voting rights (B) Common stock - -Preferred stock - -
Number of shares with limitedvoting rights according to otherlaws (C)
Common stock 233 -
Preferred stock - -
Number of shares with resurrected votingrights (D)
Common stock - -
Preferred stock - -
Number of shares with voting rights
(E = A - B - C + D)
Common stock 1,732,147 -
Preferred stock - -
-
7/24/2019 Celltrion GSC 2011 AR
22/165
18
)#
&
$" $$ $#
)* (3### (3### (3###
)* ',3"(, ,3+%# 43%$(
)* '%3,$" %35-% -3""%
)* ' ' '
)* ' ' '
)7* ' ' '
)7* ' ' '
' ' '
)7* ' ' '
' ' '
)* ' ' '
' ' '
)* ' ' '
' ' '
-
7/24/2019 Celltrion GSC 2011 AR
23/165
19
&
Dividend Repayment
Dividend Repayment in the Past 3 Years
Division 12thPeriod 11thPeriod 10thPeriod
Par value per share (KRW) 5,000 5,000 5,000
Net profit of the period (million KRW) -6,256 6,830 7,315
Earnings per share -3,612 3,943 4,223Total cash dividends (million KRW) - - -
Total stock dividends - - -
Cash dividend payout - - -
Cash dividend yieldCommon stock - - -
Preferred stock - - -
Stock dividend yield (%)Common stock - - -
Preferred stock - - -
Cash dividend per share(KRW)
Common stock
Preferred stock
Stock dividend per share
(per share)
Common stock
Preferred stock
-
7/24/2019 Celltrion GSC 2011 AR
24/165
20
""#
$#
#
4 %5&6 $(6 4
%(64 &(64
)(6 #
##
4
#
7898:;<
4 =:;>;9?@
#
A:BC8
-
7/24/2019 Celltrion GSC 2011 AR
25/165
21
II II. Business Overview
Business Overview
a) Industry Status
In recent years, investments in R&D in domestic pharmaceuticals and li fe science companies have accountedfor 2-3% of their revenues, far below the R&D investment of multi-national pharmaceutical businesses, in which
R&D accounts for nearly 15% of their revenue. Technically, the development of new material technologies is
only 25% that of developed countries. Our production technology is underdeveloped. The development of
domestic bioengineering and biotechnology is only 35-65% that of developed countries. Many bioventure
companies have emerging during these years mainly thanks to the governments encouragement to develop
this venture industry. These companies are committed to research and development on the basis of unique
technologies. In addition, large domestic pharmaceutical companies have developed revolutionary medicine. To
be accepted into the international market, they have conducted clinical experiments on human subjects in
specialized international clinical research organizations. However, they are inexperienced and face many
difficulties at the moment.
Granted the exclusive patents of advanced pharmaceutical companies in South Korea, we focus on thedevelopment of generic medicine in the domestic market and maintaining stable sales and profit. However,
due to the recent medical reform separating the prescribing and dispensing of drugs, prescriptions for foreign
original medicine have increased. As a result, domestic pharmaceutical companies are in a worse situation with
decreasing R&D investment and may even lose opportunities to develop new medicines.
To avoid this dire situation and to promote the development of the domestic biological industry:
South Korean companies should take advantage of its own high-quality talent and low production structure
to set up a domestic production base through coorperation with foreign companies which possess
advanced technologies and products. They can also make a profit through projects that are under
development or are undergoing commercialization, as well as through direct or indirect investments inproducts (medicine, medicine for external use, etc.).
We should seek out profitable overseas bio projects and create opportunities for domestic investors to
participate in them. This way, investors can make a profit, and at the same time technology transfers will
become possible.
We should see to it that excellent domestic bioventure companies possessing their own technologies
receive adequate financial support by attracting investment, so that their business models can be scaled
and industrialized.
We should help domestic bioventures, which possess self-developed technologies, to attract investment,which helps them industrialize their business.
We should promote our business through direct or indirect investments in profitable domestic and overseas bio
projects, and by securing elusive patents in other countries and regions. On one hand, we should do research on
basic bioengineering technologies and make investments in production infrastructure; on the other hand, we
should attract advanced foreign companies to build local bases for mass production and gradually advance the
development of profitable technology. In this way, we can upgrade the biological industry the sunrise industry
with high added value in the 21st century into a mainstream national industry boasting competitive strength.
-
7/24/2019 Celltrion GSC 2011 AR
26/165
22
#
0
%/// ) 4
4 4
4
4 4
4
#
$ ,*?J789-
,H?KK?@;?9 L8@@0LF@DF:8 M8O-
,MN8:?P8FD;< A:BD8;9G-4
,-
4
4
#
0
4
#
4 %
#4
4
4
4 LB@I0 LN?;9 4
4
#
0
#
$ #
##
L=QRLST"U LV=
-
7/24/2019 Celltrion GSC 2011 AR
27/165
23
b) Our Company Status
' Biotechnology investment projects
Established in June 2000, our company relies on international talent with years of experience in the planning
and proproposal of overseas projects. We focus on developed coutries and regions, including the US, Europe
and Japan.
Our company is seeking companies engaged in great biotechnology projects, appraising their researchprograms, investing directly and maintaining investments from domestic investors.
Our company combines foreign companies which possess advanced biotechnology with domestic capital, and
plans and promotes the establishment of joint ventures in South Korea.
Our company is engaged in the procurement of raw materials for biopharmaceutical production from
domestic and overseas suppliers, as well as the distribution of these products.
Our companys first investment project is a good example. In order to develop various therapeutic proteins for
the production of vaccines and anticancer drugs, it used the Mammalian Cell-Culture Technology of the VaxGen
Company, and established a joint venture named Celltrion. Our company will build on this achievement and
continue to promote profitable new projects.
' The localization of excipients for biopharmaceutical production
The demand for equipment for biopharmaceutical production is increasing sharply worldwide, and the market
for raw materials and excipients will expand along with it. It is necessary to purchase raw materials for
biopharmaceutical production from domestic and foreign suppliers, and upgrade the relevant distribution
channels.
In order to adjust to the change in business structure and maintain quality and price competivemess, our
company is planning to carry out its second round of commercial projects, aiming at the localization ofexcipients for biopharmaceutical production.
To this end, since most raw materials and excipients for basic biopharmaceutical production are imported from
overseas, our company plans to promote cooperation with overseas companies to establish joint efforts to
promote the technologies necessary for the development of these materials. Meanwhile, it will advance the
localization of these materials and expand its Asian market through the diversification of material production,
investment in cold-chain logistics, and the construction of domestic bases for material production.
' Procurement of reference drug
In physical and chemical comparison tests and clinical trials with originators, control tests are crucial for thedevelopment of biosimilars. Notably, the number of reference drugs used in the clinical trials of biosimilars is
even larger than the total of those used in several Eastern European countries over an entire year. It is a well
known fact that the pharmaceutical companies from which drugs originate from usually restrict the purchase of
reference drugs in order to impede the development of biosimilars.
Since its establishment, our company has run overseas projects for many years. With networks and
coldchain operation capabilities, we first started the business of the bulk purchasing reference drugs with a
price advantage, which is hard to achieve even for specialized international clinical research organizations.
Moreover, we continue to supply the development and clinical use of biosimilars. Recently, we have
expanded our business in Japan, including the supply of reference drugs for domestic clinical use and
ordering products from Japanese pharmaceutical companies.
-
7/24/2019 Celltrion GSC 2011 AR
28/165
24
4
#
4 L=QRLST"U
WU=XS=X L=QRLST"U
7Q=ETQ #
0
2/6 Y21
1/6
#
4
#
-
7/24/2019 Celltrion GSC 2011 AR
29/165
25
Since many domestic and foreign companies may eventually transition towards biosimilar production, our
company plans to increase its purchases of reference drugs, as well as its global coldchain distribution
capabilities through its overseas network and reference drug supplies.
' Agricultural goods supply to Russia
The main crop of Russia is grain, though vegetables and fruits are also grown. Due to severely inadequate
production, 90% percent of the fruits and vegetables consumed in Russia are imported. Since 1998, the
consumption of fruits and vegetables has increased by more than 80%. The agricultural producers in Russia
are advancing plastic greenhouse agriculture in large areas.Therefore, after signing agreements with local
legal personnel in Russia, our company is supplying goods to them and plans to increase capabilities within
this area.
-
7/24/2019 Celltrion GSC 2011 AR
30/165
26
%#
#
)& 3 7*
)* )*
' =CD ECFF/GD (3#%#)$+2#4* +-#)-$25#* '
' $5345#)4$2$"* +-#)-$25#* '
' %(")$2",* "-)$2"#* '
' =HI (()#2$5* -)#2"#* '
' "3(54)52%%* "54)$-2+$* '
' "43+"-)$##* "3##()$##* '
#
)& 3 7*
$" $$
$3(%4 +2$$
' ' ' '
' '
$3(%4 +2$$
"43+"- $##2## $43-"4 5$2+5
' '
' '
' '
"43+"- $##2## $43-"4 5$2+5
"43+"- $##2## $+35,- $##2##
-
7/24/2019 Celltrion GSC 2011 AR
31/165
27
Sales details
a) Status of Major Products
Unit: KRW MN
Business Sectors Sales (Percentage) Gross Profit(percentage) Remarks
Air filter 5,030 (18.07%) 840 (41.90%) -
Biosimilars 19,790 (71.12%) 840 (41.90%) -
Chemical generics 352 (1.26%) 24 (1.20%) -
API 55 (0.19%) 4 (0.20%) -
Machinery 2,597 (9.33%) 297 (14.81%) -
Total 27,824 (100%) 2,005 (100%) -
b) Sales Breakdown by Sales Methods
Unit: KRW MN, %
Categories12thperiod 11thperiod
Sales Percentage Sales Percentage
Export sales
Sales of products not producedby Celltrion GSC 1,537 8.11
Sales of self-produced products - -
Sales of agent products - -
Others - -
Subtotal 1,537 8.11
DomesticSales
Sales of products not producedby Celltrion GSC
27,824 100.00 17,427 91.89
Sales of self-produced products - -
Sales of agent products - -
Others - -
Subtotal 27,824 100.00 17,427 91.89
Total 27,824 100.00 18,964 100.00
-
7/24/2019 Celltrion GSC 2011 AR
32/165
28
#
,$-
=IJ KILMAJ
,%-
c) Sales Channels and Sales Methods
-
7/24/2019 Celltrion GSC 2011 AR
33/165
29
c) Sales Channels and Sales Methods
(1) Sales organization
(2) Sales channels
Air Filter In-house direct sales
Reference drugs, etc. In-house direct sales
Plastic greenhouse materials In-house direct sales
Supp iers omestic an overseas
Korean ranc es o oreigncompanies
T e Company C ients
,&-
-
7/24/2019 Celltrion GSC 2011 AR
34/165
30
,&-
0 .
0 : ,$( $ -$(
,'-
0
0
-
7/24/2019 Celltrion GSC 2011 AR
35/165
31
(3)Sles methods and conditions
' Sales methods: supplies based on supply contracts or orders from customers
' Payment terms:after settling sales with customers (within 15 days to one month), cash payment should
be made within 15 days;after monthly sales settlement with customers, cash payment should be made
no later than the last day of the next month
(4) Sales strategy' Cooperate with target corporate clients and expand market by expanding the variety of applicable products
' Strict quality control and just-in-time management of the import and supply chain
-
7/24/2019 Celltrion GSC 2011 AR
36/165
32
# ,- )& 3 7*
$" $$
=CD ECFF/GD ' ' ' '
(3#%# $+2#4 %34+" $525-
' ' ' '
$5345# 4$2$" $%3,-( 4$25(
' ' ' '
%(" $2",
' ' $3(%4 +2$$
' ' ' '
=HI ' ' ' '
(( #2$5 ' '
' ' ' '
"3(54 52%% ' '
"43+"- $## $+35,- $##
-
7/24/2019 Celltrion GSC 2011 AR
37/165
33
# Sales status
a) Export (domestic sales) by categoryUnit: KRW MN,%
Item Categories 12
th
period 11
th
periodAmount Percentage (%) Amount Percentage (%)
Air filterExport - - - -
Domestic sales 5,030 18.07 3,782 19.94
BiosimilarsExport - - - -
Domestic sales 19,790 71.12 13,645 71.95
Chemical genericsExport - - - -
Domestic sales 352 1.26
Plastic greenhousematerials
Export - - 1,537 8.11
Domestic sales - - - -
API
Export - - - -
Domestic sales 55 0.19 - -
MachineryExport - - - -
Domestic sales 2,597 9.33 - -
Total 27,824 100 18,964 100
# ,- )& 3 7*
-
7/24/2019 Celltrion GSC 2011 AR
38/165
34
$" $$
=CD ECFF/GD ' ' ' '
-3-(4 $,24- "345" $,2-4
$53"4$ 4"2-# $%3$%$ 442--
$( #2#, ' '
%"+ $2"% ' '
' ' ' '
' ' ' '
' ' $3#%- ,2#5
=HI $%, #2($ ' '
-5 #2$+ ' '
$3"-" -2,, ' '
$3$$5 -2"# ' '
",3,$4 $##2## $,35(4 $##
b) Import (domestic purchase) by categoryUnit: KRW MN %
-
7/24/2019 Celltrion GSC 2011 AR
39/165
35
Unit: KRW MN, %
Item Categories12thperiod 11thperiod
Amount Percentage (%) Amount Percentage (%)
Air filter
Import - - - -
Domesticpurchase
4,457 16.74 2,792 16.47
Biosimilars
Import 19,271 72.40 13,131 77.44
Domesticpurchase
15 0.06 - -
Chemical generics
Import 328 1.23 - -
Domesticpurchase
- - - -
Plastic greenhousematerials
Import - - - -
Domesticpurchase
- - 1,034 6.09
API
Import 136 0.51 - -
Domesticpurchase
49 0.18 - -
Machinery
Import 1,242 4.66 - -
Domesticpurchase
1,119 4.20 - -
Total 26,617 100 16,957 100
,-
-
7/24/2019 Celltrion GSC 2011 AR
40/165
36
# ,-
)& 3 7 *
=CD ECFF/GD ' '
(3#%# $+2#4
$5345# 4$2$"
%(" $2",
=HI
(( #2$5
"3(54 52%%
"43+"- $##2##
-
7/24/2019 Celltrion GSC 2011 AR
41/165
37
c) Export (domestic sales) by business region
Unit: KRW MN, %
Item Categories Target country Amount Percentage Remarks
Air filter
Export - -
Domestic sales Domestic 5,030 18.07
BiosimilarsExport
Domestic sales Domestic 19,790 71.12
Chemical
generics
Export
Domestic sales Domestic 352 1.26
API
Export
Domestic sales Domestic 55 0.19
MachinaryExport
Domestic sales Domestic 2,597 9.33
Total 27,824 100.00
-
7/24/2019 Celltrion GSC 2011 AR
42/165
38
# ,-
)& 3 7*
=CD ECFF/GD ' ' '
-3-(4 $,24-
--4 $2,+
$+3445 4#2((
-- #2$4
$( #2#,
%"+ $2"%
' '
=HI $%, #2($
(# #2$5
+"% %2#5
"#, #244
$(" #2(4
,$ #2"%
$3$$5 -2"#
",3,$4 $##2##
-
7/24/2019 Celltrion GSC 2011 AR
43/165
39
d) Import (domestic purchase) by business regionUnit: KRW MN,%
Item Categories Target country Amount Percentage Remarks
Air filterImport - - -
Domestic purchase Domestic 4,457 16.74
BiosimilarsImport
Germany 447 1.68
U.K. 18,779 70.55
Switzerland 44 0.17
Domestic purchase Domestic 15 0.06
Chemical genericsImport U.S. 328 1.23
Domestic purchase Domestic - -
APIImport India 136 0.51
Domestic purchase Domestic 50 0.19
Machinary Import Germany 823 3.09
Japan 206 0.77
U.S. 152 0.57
Italy 61 0.23
Domestic purchase Domestic 1,119 4.20
Total 26,617 100.00
-
7/24/2019 Celltrion GSC 2011 AR
44/165
40
'#
#
,$-
)& 3 *
' ' '
' ' '
3
,%- ,-
,&-
,-
#
, -
#
,$-
,-
,%-
)& *
$% $- $(
4( "# "( %#
4( "# "( %#
-
7/24/2019 Celltrion GSC 2011 AR
45/165
41
$
Status of operation equipment
a) Status of Commercial Equipment
(1) Domestic
Unit: KRW MN
Category Location Land Building Total Number of employees Remarks
- - -
Total - - -
* The rented HQ office is in use
(2) Overseas
No related issue
(3) Plans for new branches establishment
No related issue
b) Other Commercial Equipment
No related issue
c) Plans for Purchasing New Equipment
(1) Ongoing investment
No related issue(2) Future investment plans
Business
SectorName of Plan
The Total ExpectedInvestment
Expected Investment by PeriodInvestment
EffectRemarks
Assets from Amount 13thPeriod 14thPeriod 15thPeriod
EquipmentEquipment,
etc.75 20 25 30
Improved officeefficiency
Total 75 20 25 30
(#
,-
-
7/24/2019 Celltrion GSC 2011 AR
46/165
42
4
#,. -
)*
"#$#2#$2#( $-#3### 4,"3-44 '"",3($" $- $"
4,"3-44 '"",3($"
)#
"#$$2#-2"
5
)*
"#$$2#(2#
(
?ALLMJINO @NO LL? )
*
"#$$2#(2%
#
?ALLMJINO ?N23LM@2
"#$$2#,2"
5
"#$$2#,2"
5
P:Q/GD RS00FT =UDGGVGW/ OC00XW Y:T:ZS
Z#
,-
% Details on derivative goods
This year, we signed a contract with Woori Bank to guarantee a certain amount of return for investors who
sell the stocks of Celltrion and to allocate the excessive return to them should the scenario arise The relevant
-
7/24/2019 Celltrion GSC 2011 AR
47/165
43
sell the stocks of Celltrion, and to allocate the excessive return to them should the scenario arise. The relevant
balances are as follows: (Unit: KRW 000)
Signing Date Counterparty Target Shares Trading Profit Gains (Losses) Remarks
Jan 5 2010 Individual 140,000 shares 762,477 -226,512
120,000 out of 140,000
shares were sold
Total 762,477 -226,512
& Major operating contracts, etc.
Category Date of contract Content of contract Counterparty
Projectconstruction
contract
Apr 29 2011
Contracts for plastic greenhouseconstruction and supplementaryservices in Russia
Bogwang Construction Corporation
Projectconstruction
contractMay 5 2011
Service contract for plasticgreenhouse construction in Russia Russian legal person
Purchasecontract
May 30 2011 Purchase contract for generics CELLTRION CO.,LTD.
Trust contract forassets
managementJun 29 2011
Trust contract for the managementof fixed benefit pensions
Hana Bank
Purchasecontract Jun 29 2011 Master Supply Agreement Nippon Kayaku
(
Research and development activities
No related issue
1#
#
-
7/24/2019 Celltrion GSC 2011 AR
48/165
44
[\ )& *
"%3#"- # # "%3#"-
# # # #
# # # #
# # # #
$$3### # $$3### #
"3-%( $-3### # $,3-%(
%,3-(5 $-3### $$3### %53-(5
)* # # # #)* ""3### # # ""3###
)* +3,," # +3,,"
)* # # # #
)* # # # #
)* # # # #
# # # #
%#3,," # # %#3,,"
# # # #
(3-## # # (3-##
4"3("$ $-3### $$3### 4(3("$
) * &
& ""3###
# &
,-
)
Other information necessary for investment decisions
a) Summary of external financing
Domestic Financing Unit: KRW MN
-
7/24/2019 Celltrion GSC 2011 AR
49/165
45
Financing SourceBeginningBalance
New FinancingReductionthrough
RepaymentEnd Balance Remarks
Banks 23,024 0 0 23,024
Insurance companies 0 0 0 0
Comprehensive financial companies 0 0 0 0
Commercial credit companies 0 0 0 0
Mutual savings bank 11,000 0 11,000 0
Other financial institutions 2,435 14,000 0 16,435
Subtotal of financial institutions 36,459 14,000 11,000 39,459
Corporate bonds (public offering) 0 0 0 0
Corporate bonds (private placement) 22,000 0 0 22,000
Share offering (public offering) 8,662 0 8,662
Share offering (private placement) 0 0 0 0
Asset securization (public offering) 0 0 0 0
Asset securization (private placement) 0 0 0 0
Others 0 0 0 0
Subtotal of capital market 30,662 0 0 30,662
Shareholders, executives, subsidiary 0 0 0 0
Other 5,400 0 0 5,400
Total 72,521 14,000 11,000 75,521
(Reference) total number of corporate bonds issued in this periodPublic offering: KRW MNPrivate placement: KRW 22,000 MN
b) Credit rating in the past three years
(N/A)
"""#
$#
-
7/24/2019 Celltrion GSC 2011 AR
50/165
46
,. -
$" $$ $#
[\ ($3-#4344,3"%, -43+4#35(43+-- %$3--"3-$(3((+
(#3,#53,#"3%%5 -43+4#35(43+-- %$3-%(3+++3#-%
45+3$4%3+54 ' ,3("43($(
[\ %+#3--#3++43$"+ %,435"%3+%"3%4# $4#3+5-3-5(3,4#
%+#3-%53%543#(+ %,435$(3(4-3(## $4#3++(3,+(3###
$3"#%3%%- -$%3%%- 4"%3%%-
"+,34%, ("53(%, 44"3%%,
43%$(3### 43%$(3###
-%$3+-+3,,%3%,- -$(345-345#3"$- "#"3%%,35$$3""+
[\ +"355"35+#35%+ +%3,4(34$(355$ ,,3"#,3($$35,#
[\ +$34-+3-5"3%4- ,53#--3"$(3$%" "43,$$3-+(3("%
$,-34-$3-4%3%$" $("34$535%$3$"% 5%3+$435543-+%
[\ +3,,$35##3### +3,,$35##3### +3,,$35##3###
[\ (543%%%344" (543%%%344" (543%%%344"
[\ '$%#3$--3$+# '$5-3,%%344# $#%3,,-35%-3-+$[\ ",$34,5345"3$+- "($3%5#3",,3455 '-3"$#3,"#34%+
[\ '%345$3,5$34"- "3,$5355"3"5# '$5-3,%%344#
",43$#43$5#3#(" ",%3#4-3+(53#5$ $#+3($+35$%34-(
"43+"-3%4,3%"5 $+35,-3,,-3#-% 43,$"3,%(3$"#
5#%3-$53,4$ $3$,53-$$3-"" $3($-3((43"55
'43$#$3"%"3#5$ 53-,,3"("3"+, -3,"%3"-43,#+
',3%-43$5-3-"- ,3+%#3,$%3#"+ 43%$(3"+"3(4%
I
III Financial summary
Financial detailsUnit: KRW
-
7/24/2019 Celltrion GSC 2011 AR
51/165
47
Unit: KRW
Classification 12thPeriod 11thPeriod 10thPeriod
Current assets 51,407,776,236 47,870,957,844 31,442,415,558
Quick assets 50,609,602,339 47,870,957,844 31,435,888,043Inventories 798,173,897 - 6,527,515
Non-current assets 380,440,887,128 367,923,832,370 170,894,495,670
Investment assets 380,439,397,058 367,915,574,500 170,885,685,000
Tangible assets 1,203,334 413,334 723,334
Intangible assets 286,736 529,536 772,336
Other non-current assets 7,315,000 7,315,000
Total assets 431,848,663,364 415,794,790,214 202,336,911,228
Current liabilities 82,992,980,938 83,675,715,991 66,206,511,960
Non-current liabil ities 81,748,492,374 69,044,215,132 27,611,485,523
Total liabil ities 164,741,473,312 152,719,931,123 93,817,997,483
Equity 8,661,900,000 8,661,900,000 8,661,900,000
Captial surplus 597,333,772 597,333,772 597,333,772
Capital adjustment -130,144,180 -194,633,770 103,664,934,481
Other accumulatedcomprehensive income
261,769,792,184 251,390,266,799 -4,210,620,738
Retained earnings -3,791,691,724 2,619,992,290 -194,633,770
Total equity 267,107,190,052 263,074,859,091 108,518,913,745Sales revenue 27,824,376,329 18,964,664,043 7,612,635,120
Operating income 903,419,671 1,169,411,422 1,514,557,299
Profit from continuousoperation
-7,101,232,091 9,466,252,286 4,623,247,608
Net profit -6,347,194,424 6,830,613,028 7,315,282,573
[%#
-
7/24/2019 Celltrion GSC 2011 AR
52/165
48
)$*
"#$$ $ $
2 ]]"2- "2+5
2
22
2
3
2
2
3
%
3 2
2
2
2
$ 3
3
2
2
3
2 3
)*3
2
3
3
2
-
7/24/2019 Celltrion GSC 2011 AR
53/165
49
Attention in the use of financial statements(1) Summary of significant accounting policies
Since the beginning of this financial period, the Company has adopted the General Corporate Accounting
Standardswhich was applicable to the financial years after 1 January 2011. Therefore, the statements of
retained earnings prepared before in accordance with the previous GAAP are publicized as notes of financial
statements in compliance with paragraphs 2.4 and 2.89 of Preparation and Presentation of Financial Statements
of theGeneral Corporate Accounting Standards.The adoption has no influence on the business performance,
financial status and announcements of the Company.The significant accounting policies in the Company's
financial statements are as follows:
a) Revenue recognition criteria
The Company recognizes revenue on a delivery basis. Other revenues are recognized when the amount can be
reliably measured and when it is probable that future economic benefits will flow to the Company.
b) Cash and cash equivalents
The Company classifies the marketable securities and short-term financial instruments, which the repayment
period is less than three months, the value dont change laregely with the interest fluctuation, can be converted
into cash without large transaction cost, as cash and cash equivalent. The cash flow statements use the samecretiria.
c) Allowance for bad debts
The Company has set an allowance based on the expected amount and rate of bad debts, which is derived
from past experience.
d) Financial instruments
The Company classifies time deposits for the purpose of short-term capital operations, time deposits, and
periodical deposits of financial institutions with a maturity date less than 1 year as short-term financial
instruments. Financial instruments which do not belong to current assets are classified as long-term financial
instruments.
-
7/24/2019 Celltrion GSC 2011 AR
54/165
50
2
3
3
2
2
3
2
2
3
3
2
2
2
2
2
2
(
-
7/24/2019 Celltrion GSC 2011 AR
55/165
51
e) Inventories
The Companys inventories are determined on the basis of the perpetual inventory method and regular inventory
inspection. The inventory value is calculated by the total average method and is recorded as a purchase cost.
The market value of inventory is recorded in the financial statements by inventory classification. When the
market value of the inventory is lower than the purchase costs, the valuation loss of inventories is included into
costs of goods sold and at the same time is recorded in the balance account of inventories. However, when there
is no devaluation in the inventory value and the market value is higher than the book value but lower than the
purchase costs, the valuation loss is reversed and deducted from costs of goods sold.
f) Classification and valuation of marketable securities
Marketable securities purchased for short-swing profits, when transactions happen frequently, are classified asshort-term trading securities. Securities with specific maturity dates and specified repayment amounts, and thecompany had the intention and ability to hold to maturity, are classified as held-to-maturity investments. Thoseexcluded from the above two categories are classified as available-for-sale financial assets.
The acquisition cost of marketable securities equals the market price paid at the acquisition, using the movingaverage cost method, plus the incidental cost.
Short-term trading securities and assets available for sale are appraised at the fair value. Since the fair value ofnon-marketable equity securites in the available-for-sale financial assets cannot be reliably measured, they are
appraised at the acquisition cost. For securities without a market price, its fair value equals the future cash flowscalculated by the discount rates set by authoritative independent credit rating institutions according to differentcredit ratings.
Unrealized gains of short-term trading securities are included into the current profit or loss, whereas theaccumulated gain or loss of the available for-sale securities is recognized as a gain or loss on the balance sheetafter disposal of the securities or recognition of impaired loss. When a marketable securitys recoverable amountis lower than the acquisition cost after depreciation for securities or the acquisition cost for equity securities, theyare included into asset impairment losses and are reflected in the current profit or loss.
Held-to-maturity investments are valued at acquisition cost after depreciation. During the depreciation period, thespread between the acquisition cost and the Book Value at the date of maturity is discounted by the effective
interest rate method and is deducted fromthe acquisition cost, then added by the interest income.
When a marketable securitys recoverable amount is lower than the acquisition cost after depreciation forsecurities or the acquisition cost for equity securities, is it included into the asset impairment losses and reflectedin the current profit or loss.
g) Valuation and depreciation of tangible assets
The Companys tangible assets are measured by the acquisition cost minus the assets impairment loss andaccumulated depreciation calculated based on the expected useful life and the depreciation method in thefollowing chart:
Classification Useful life Depreciation method
Facility 5 years Straight-line method
-
7/24/2019 Celltrion GSC 2011 AR
56/165
52
3
2
3
2 3
2
2
3
2
(
3
2 3
2
2
$
2
3
2 3 2
-
7/24/2019 Celltrion GSC 2011 AR
57/165
53
If an expenditure on tangible assets at acquisition or after installation can increase the future economic benefits,
it is treated as a capital expenditure. Otherwise, it is treated as an expense of the period.
In addition, when the future economic benefits of tangible assets are significantly lower than their book value
due to obsolescence or a sharp market valuation decrease, asset impairment losses are recognized as the
difference between the book value and the recoverable value. However, when the recoverable amount of the
impaired assets in the next period is higher than the book value, the excess amount above the book value but
lower than the ini tial carrying amount after deducting depreciation, was reverse in the asset impairment losses.
h) Valuation and depreciation of intangible assets
The cost of the Companys intangible assets is measured with the production cost or the purchase cost in that
year plus the incidental cost and minus depreciation calculated on the basis of the expected useful life and
depreciation method in the following chart:
Classification Depreciation Expected useful life
Right for trademark Straight-line method 5 years
In addition, in the event that the recoverable amount of intangible assets is significantly lower than the book
value due to obsolescence or sharp market value decrease, the book value shall be adjusted to the recoverable
amount, and the difference shall be recorded in the account of impairment losses for intangible assets under the
current profit or loss. When the recoverable amount of the assets whose values have been deducted by
impairment losses is higher than the book value, the excess amounts that lower than the initial carrying amount
after amortization, were reversed in the asset impairment losses.
i) Pension benefit liabilities
The Company has a defined contribution plan. According to the regulations on employee pension payments, the
estimated total amount of pension which needs to be paid to retirees who used to be full-time employees of the
Company for at least 1 year before the end of the report date is set as a pension benefit liability.
The Company has deposited the defined benefit pension in Hana Bank. The Companys contribution is recorded
as a pension plan asset and is deducted from pension benefit l iabilities. When the pension plan assets exceed the
total amount of pension benefit liabilities, the excess amount is recorded in the investment assets account. In
addition, the pension plan assets are composed of time deposits, etc.
2
2 3
-
7/24/2019 Celltrion GSC 2011 AR
58/165
54
2
23
2
2
3
2
2
%
3
2
2 )*
3
2
2
3
2
2
3
2
2
2 3
2
j) Convertible corporate bonds and bonds with warrants
The Company separates the liabilities equity parts in the accounting treatment of convertible corporate bonds
-
7/24/2019 Celltrion GSC 2011 AR
59/165
55
The Company separates the liabilities equity parts in the accounting treatment of convertible corporate bonds
and bonds with warrants. The liabilities are recognized at the fair value of ordinary corporate bonds without
conversion rights or warrants, and the fair value is measured by the present value of the expected future cash
flows. The value of conversion rights or warrants is derived by deducting the value of bonds in the liabilities part
from the total value of corporate bonds, and is recorded into capital surplus.The liabilities part is discounted by
the effective interest rate method, whereas the equity part will not be measured after initial recognition.
k) The conversion of foreign currencies and liabilities
The Company converts foreign currencies and liabilities based on the closing exchange rate at the end of the
reporting period, and gains or losses via foreign currency conversion are included in the current profit or loss.
l) Amortization of discount on capital stock
In the first three years after the stock issuance year or the capital increase year, the discount on capital stock
is amortized by the same amount every period. This amount is included in the appropriation of retained
earnings. In the event that the retained earnings are negative or less than the amortization amount, theamount will be amortized the following year.
m) Income tax expense and deferred income tax assets (liabilities)
The Company, according to Income Tax Law, calculates its income tax expense as the total of income taxpayable and additional tax of the business year plus or minus the change in the deferred income tax of thebusiness year. The deferred income tax assets and liabilities are respectively determined by the differencebetween their book value and tax bases.
The deferred income tax assets and liabilities are respectively measured at the reduced amount and extra
amount of income tax in the future due to the disappearance of the temporary difference.The effect of thetemporary difference on income tax is reflected on income tax expenses, whereas the effect on equity is directly
reflected on the equity account.Deferred income tax assets are treated as assets when they can reduce the tax
on taxable income.
Deferred income tax assets and liabilities are divided into current and non-current accounts. When the deferredincome tax assets and liabilities in the same current and non-current accounts are filed to the same tax authority,they are balanced against each other and are marked.
n) Contigent liabilities
As the Company performs the present obligations because of past events or transactions, when it is probable
that recources will flow out and when the loss can be reliably measured, the loss is included into liabilities.Inaddition, contigent liabilities are recorded when the Company recognizes potential obligations according to past
events or uncertain future events. If present obligations exist because of past events or transactions, contigent
liabilities are also recorded if it is not probable for resources to flow out or when the amount of the obligations
cannot be reliably measured.
,%-
,-
,&-
-
7/24/2019 Celltrion GSC 2011 AR
60/165
56
,&-
,-
#
,$- &
)& 3 7*
$" $3%%- $% #2547
%"3,#5 %", #2557
4"# 4 #2547
%-3,,% %-, #2557
$$ (++ , $2#"7
"$34", "$4 $2##7
"3(#" "( $2##7
"-3+$, "-+ #2557
$# $#" $ #25+7
"+35-" "+5 $2##7
"53#-- "5# $2##7
,%- &
)& *
$"
$$
$#
$2 "-+ "5# -%
"2 () ' ' ' $4
)*
$"
(
%2 )* 55 ' -" ",-
-2 %-4 "-+ "5#
(2) Any violation of accounting standards
(3) Other matters worth attention: N/A
-
7/24/2019 Celltrion GSC 2011 AR
61/165
57
3. Matters concerning accounting information
a) Status of allowance for bad debts
(1) The allowance for bad debts in the past three business years by account(Unit: KRW MN, %)
Classification Account Total Liabilities Allowance for Bad Debts Loan Loss Reserve Ratio
12thperiod
Accounts receivable 1,334 13 0.97%
Short-term loans 32,609 326 0.99%
Accrued income 720 7 0.97%
Total 34,663 346 0.99%
11thperiod
Accounts receivable 588 6 1.02%
Short-term loans 21,726 217 1.00%
Accrued income 2,502 25 1.00%
Total 24,816 248 0.99%
10thperiod
Accounts receivable 102 1 0.98%
Short-term loans 28,942 289 1.00%
Total 29,044 290 1.00%
(2) Status of change in allowance for bad debt in the past three business years(Unit: KRW MN)
Classification 12thPeriod 11thPeriod 10thPeriod
1. Beginning balance of allowance for bad debts 248 290 43
2. Net bad debt expense() - - 17
Bad debt expense (book value of bad debts)
Recovery amount of bad debts 12
Other changes 5
3. Allowance for bad debts (reversal) 99 42 264
4.Total ending balance of allowance for bad debts 347 248 290
,&-
0
-
7/24/2019 Celltrion GSC 2011 AR
62/165
58
#
,'-
)& *
, ,
$
$
% %
' ' ' ' '
$3%%- ' ' ' $3%%-
$3%%- ' ' ' $3%%-
$## ' ' ' $##
#
,$- &
)& 3 7*
$" $$ $# %%, ' '
=IJ KILLAJ ",4 ' ' '
' ' , '
=HI $%- '
,$
45+ ,
)7*
[^_$##\
#2$+(7 #2###7 #2##%7 '
)*
[^`)*^"a\
,524 ,%"$24 $",+2+ '
(3) Policy on the setting of allowance for bad debts related to accounts receivable
-
7/24/2019 Celltrion GSC 2011 AR
63/165
59
For accounts receivable balance, the allowance for bad debts is set by the bad debt rate based on past
experience and expected bad debt rate.
(4)Status of the balance of accounts receivable by age at the end of the period (Unit: KRW MN)
Classification 3 Years Total
Amount
General - - - - -
Special party 1,334 - - - 1,334
Total 1,334 - - - 1,334
Proportion 100 - - - 100
b) The holding and physical inspection history of inventories
(1).Status of inventory holding by business sector in the past three business years
(Unit: KRW MN, %)
Business Sector Accounts 12thPeriod 11thPeriod 10thPeriod Remarks
Biosimilars Goods 336 - -
Air Fillter Goods 267 - - -
Chemical generic Goods - - 6 -
API Goods 134 -
Machinery Goods 61
Total 798 6
The ratio of inventories to total assets (%)[inventories total assets at the end
of the period !100]0.185% 0.000% 0.003% -
Inventory turnover (times)[annual cost of goods sold {(beginning inventory + closing
inventory) 2}]
69.7 6321.7 1268.8 -
,%-
-
7/24/2019 Celltrion GSC 2011 AR
64/165
60
0
4 #
,-4
# 4
4
#
0
#
# (
"##+
# (
)& *
$" ),3%-4* )* "
5 )-3%"-* F:SW
-
7/24/2019 Celltrion GSC 2011 AR
65/165
61
(2) The physical inspecition history of inventories, etc
- The quantity of inventories at the end of the period is determined on the basis of the perpetual inventory
system and regular physical inspections. The value of inventories is measured by the total average method andis recorded as purchase cost. When the market value of inventories is lower than the purchase cost, the
difference (net realizable value) is included into the balance sheet by inventory classification while the loss on
valuation of inventories is included into the balance account of inventories and is added into cost of goods sold.
However, when such situation that inventories are devaluated disappeared and the new market value is higher
than the book value, but do not exceed the initial carrying amount,reverse the loss from cost of goods sold and
marked it at the same time.
- Other matters
The inventory difference between the inspection date and the balance sheet date is recognized by the
Companys goods delivery certificates and goods reception certificates
c) Change in accounting standards in recent 5 business years and the reasons
Financial year Accounting change Reason for change
2008 The investment evaluated by the equity method in
the last period was reclassified as available-for-sale
securities
The significant influence was forfeited and
was therefore reclassified as available-for-
sale securities
d) The losses in recent 5 business years and the reasons(Unit: KRW MN)
Business years Loss in this period The reason
The 12thperiod (6,347)
On the closing date of this report, Tomato Bank believed that it was
difficult for the invested enterprise to recover the net assets, so the
impairment loss is recognized in the current period.
The 9thperiod (4,324)
The launch of the new goods still keeps on. Due to the change inthe investment fund, financial cost was recognized as a loss in thecurrent period.
The 8thperiod (587)
-
7/24/2019 Celltrion GSC 2011 AR
66/165
62
# ( &/6
)& *
$$ ,3+%# $8" $
$# 43%$( "##, 3
"##+ +
e) The introduction of recent 5 business years, in which the YoY growth of net profits increased by 30% or in
-
7/24/2019 Celltrion GSC 2011 AR
67/165
63
) y , g p ywhich the net profits turned to positive; reasons for changes in net profits
(Unit: KRW MN)
Businessyears
Net profits The reason
The 11thperiod 6,830
The net profits in current period increased thanks to the profits in acquisition ofstock options, including the first and second convertible bonds and the firstcorperate bonds with warrants.
The 10th
period7,315
In 2006, the transaction of call and put options, through which Woori Bank andCelltrion sell the stocks, were recognized as short-term liabilities; the net profitsincreased due to the disposal of investments in back-door listing in August 2008.
-
7/24/2019 Celltrion GSC 2011 AR
68/165
64
'#
#
$" "#$$2 $"2 %$
$$ "#$#2 $"2 %$
)& *
$" )* $$ )*
. ($3-#4344,3"%
,
-43+4#35(43+-
-
)$* (#3,#53,#"3%%
5
-43+4#35(43+-
-
$2 ) 53$(* +34%(354#35(# $$3$553((#3,5
+
"2 ) %3$(* %"3,#53%-%3%,
-
"$34"(3(4%354
4
)%",3#5"35%-* )"$43"((3"-#*
%2 ) $(* $3%%%344,3"4# (+43("53%,#
)$%3%%434,%* )(3+4(3"5-*
-2 ) $(* 4$535,+3+4% "3(#$34+,3+(+
)43$553,+5* )"(3#$43+,5*
(2 ' -3#5(3($+3+%%
,2 "354#35%-3#$- -345535#,3(,-
42 ) $"* $$(3%((3"4" '
+2 ) +* ' $3%443(++35-#
52 ) $"* -3-4#3++%35+" $3+%$3,($3#$4
4. Financial statement
Balance sheet
The 12thperiod: 2011.12.31
The 11thperiod: 2011.12.31
(U it KRW MN)
-
7/24/2019 Celltrion GSC 2011 AR
69/165
65
(Unit: KRW MN)
Accounting The 12thperiod The 11thperiodAsset
.Current assets 51,407,776,236 47,870,957,844
(1)Quick assets 50,609,602,339 47,870,957,844
1. Cash and cash equivelent 8,735,970,950 11,199,550,698
2. Short-term Investment (note 3,15) 32,609,343,364 21,725,573,977
Provision for bad debt (326,092,934) (217,255,240)
3. Account receivable(note 15) 1,333,776,270 587,529,360
Bad debt provision for Account receivable(13,337,763) (5,875,294)
4. Net value of Accounts receivable (note15)
719,968,873 2,501,786,858
Allowance for doubtful accounts(7,199,689) (25,017,869)
5. Other receivable - 4,095,518,833
6. Prepayment 2,970,934,014 4,799,906,564
7. Accrued tax assets (note 12) 115,355,272 -
8. Derivative commoditives(note 8) - 1,377,588,940
9. Liquid deferred income tax assets (note12)
4,470,883,982 1,831,651,017
)"* 45+3$4%3+54 '
$2 45+3$4%3+54 '
. %+#3--#3++43$
"+
%,435"%3+%"3%
4#
)$* %+#3-%53%543# %,435$(3(4-3(
-
7/24/2019 Celltrion GSC 2011 AR
70/165
(+ ##
$2 ) -343$+* %+#3%,#35+43(
+4
%,435$(3(4-3(
##
"2 4+3-#53-4$
)"*) (* $3"#%3%%- -$%3%%-
$2 +3($#3### 43%$#3###
)43%#,3,,,* ),3+5,3,,,*
)%*) ,* "+,34%, ("53(%,
)-* ' 43%$(3###
$2 ' 43%$(3###
-%$3+-+3,,%3%
,-
-$(345-345#3"
$-
. +"355"35+#35%
+
+%3,4(34$(355
$
$2 ) 53$5* $34(+3""-34%- 5(534$(355+
"2 ) 43$+3$5* %43%%(3###3##
#
%-3%%(3###3##
#
%2 ) $5* %,#3#,(3+4+ "((3-$,34"+
-2 -4$3#4535#$ 4#43-+(3$--
(2 "#3,#-3-#+ "3+(535$+
,2 ) $(3$5* "4(3"#,345$ %#"3-4$3"((
42 ) $(* %3%+(3%,"3%4$ ,3$$534#%3(#%
+2 ) $"* ' "34#53,%#35(+
52 ) 43$(3$+3$5* $43###3###3##
#
$43###3###3##
#
)$3(,(3+4-35+,
*
)"34+%3,4,3++
%*
$%3+,#35%43$5
5
$-3+(,3#+"3(4
#
)-3,-$3-+#3+5%
*
)53#--34#-34,
"*
$#2 ) 43$+3$5* (3###3###3### (3###3###3###
)%##3%%(3(+(* )(4(3(%"34"4*
(2) Inventories 798,173,897 -
1. Finished goods 798,173,897 -
. Non-current assets380,440,887,128 367,923,832,37
(1) Long-term investment 380,439,397,058 367,915,574,50
1 Available-for-sale securities (note 380 360 987 587 367 915 574 500
-
7/24/2019 Celltrion GSC 2011 AR
71/165
1. Available for sale securities (note4,7,18
380,360,987,587 367,915,574,500
2. Pension 78,409,471
(2) Tangible assets (note 5) 1,203,334 413,334
1. Consumption goods 8,510,000 7,310,000
Accumulated depreciation(7,306,666) (6,896,666)
(3) Intangible assets(note 6) 286,736 529,536
(3) Other non-current assets - 7,315,000
1. cash deposit - 7,315,000
Total assets431,848,663,364 415,794,790,214
Liabilities
.Current liabilities 82,992,980,938 83,675,715,991
1. Accounts payable (note 9,19) 1,758,224,734 959,715,998
2. Short-term loans 37,335,000,000 34,335,000,000
3. Provision for expenses (note 19) 360,065,878 255,416,728
4. Additional tax expenses 471,079,901 707,485,144
5. Advances from customers 20,604,408 2,859,918
6. Accounts payable (note 15,19) 275,206,791 302,471,255
7. Advance payment(note 15) 3,385,362,371 6,119,703,503
8.Income Tax payable (note 12)- 2,709,630,958
9. Convertible bonds(note 7,15,18,19) 17,000,000,000 17,000,000,000
Corporate bonds discounts (1,565,874,986) (2,783,676,883)
Repayment premium13,860,937,199 14,856,082,570
Adjustment of conversion(4,641,480,893) (9,044,704,762)
10. Corporate bonds with warrants(note7,18,19)
5,000,000,000 5,000,000,000
Corporate bonds discounts(300,335,585) (575,532,727)
%3%,#3+(#3%5" -3%,53-%,3#(#
)+(#3,(53"4"* )"3(("3$+"3,"
(*
$$2 ' -3-5#3#$#3+,-
$"2 ) 43$+3$5* 43("-3###3### 43("-3###3###
-
7/24/2019 Celltrion GSC 2011 AR
72/165
dart.fss.or.kr Page 30
. +$34-+3-5"3%4
-
,53#--3"$(3$%
"
$2 ) $#* "%3+4(3-+# '
)"%3+4(3-+#* '
"2 ) $"* +$34-+3-5"3%4
-
,53#--3"$(3$%
"
$,-34-$3-4%3%
$"
$("34$535%$3$
"%
.) $3$$* +3,,$35##3### +3,,$35##3###
$2 +3,,$35##3### +3,,$35##3###
. (543%%%344" (543%%%344"
$2 ) $$* (543%%%344" (543%%%344"
. )$%#3$--3$+#* )$5-3,%%344#*
$2 )$"+35453$+#* )$5%3-,+344#*
"2 ) $$* )$3$,(3###* )$3$,(3###*
. ",$34,5345"3$+-
"($3%5#3",,3455
$2 ) -3$"3$%* ",$34,5345"3$
+-
"($3%5#3",,34
55
.)*) $$* )%345$3,5$34"-
*
"3,$5355"3"5#
$2 )* )%345$3,5$34"-
*
"3,$5355"3"5#
",43$#43$5#3#("
",%3#4-3+(53#5$
-%$3+-+3,,%3%
,-
-$(345-345#3"
$-
Repayment premium %3%,#3+(#3%5" -3%,53-%,3#(#
Adjustment of subscription right)+(#3,(53"4"* )"3(("3$+"3,"
(*
11. Options payables ' -3-5#3#$#3+,-
12. Long-term current liability(note 43("-3###3### 43("-3###3###
-
7/24/2019 Celltrion GSC 2011 AR
73/165
dart.fss.or.kr Page 31
.Non-current liability +$34-+3-5"3%4
-
,53#--3"$(3$%
"
1.Retirement allowance liabilities(note10) "%3+4(3-+# '
Retirement pension )"%3+4(3-+#* '
Deferred income tax liability(note 12) +$34-+3-5"3%4
-
,53#--3"$(3$%
"
Total liabilities $,-34-$3-4%3%
$"
$("34$535%$3$
"%
Equity
.Paid-in Capital (note 1,11) +3,,$35##3### +3,,$35##3###
1. Common capital stock +3,,$35##3### +3,,$35##3###
.Capital reserves (543%%%344" (543%%%344"
1. Reduction of capital premium(Note11) (543%%%344" (543%%%344"
.Adjustment of capital )$%#3$--3$+#* )$5-3,%%344#*
1. Corporate bonds discounts )$"+35453$+#* )$5%3-,+344#*
Self-owned Shares(Note11) )$3$,(3###* )$3$,(3###*
.Other comprehensive income ",$34,5345"3$
+-
"($3%5#3",,34
55
Available-for-sale securities (Note4,12,13) ",$34,5345"3$
+-
"($3%5#3",,34
55
.Benefit (Loss) (Note 11) )%345$3,5$34"-
*
"3,$5355"3"5#
Undistributed surplus )%345$3,5$34"-
*
"3,$5355"3"5#
Total equity ",43$#43$5#3#("
",%3#4-3+(53#5$
Total liabilities & equity -%$3+-+3,,%3%
,-
-$(345-345#3"
$-
#
$" "#$$ $ $ "#$$ $" %$
$$ "#$# $ $ "#$# $" %$
)& *
$" )* $$ )*
-
7/24/2019 Celltrion GSC 2011 AR
74/165
dart.fss.or.kr Page 32
$" )* $$ )*
.) $(* "43+"-3%4,3%"5 $+35,-3,,-3#-%
.) $,* "(3+$+35#(3#$( $,35,%3,5"3$(+
. "3##(3-4$3%$- "3###354$3++(
.) $(* $3$#"3#($3,-% +%$3(,#3-,%
. 5#%3-$53,4$ $3$,53-$$3-""
. $$3$"5344%34($ "#34(-35(#35$5
$2) $(* "3+553,((3("4 $3+((3(-53%(5
"2 +##3%#%3-4(
%2 +"3(-535," %,3%($3$5(
-2 +34-53%$( (5
(2 ' -43$-(35,#
,2) -* ,3"5(3-#%3((, +3(%#3%%"3$$5
42) +* 4,"3-443%5( +34##3-"-3+4%
+2) +* ' $3%443(++35-#
52) $(* "+#3(5%3#45 "#43(((3$$4
$#2 -$3--" %3"54
. $53$%-3-"(3($% $"3-(+3$$#3#((
$2 +3(5534+,34-4 +3-(,3(5#3+5,
"2 "$"34+53""5 (534,#3,#(
%2 $,+3$"" -3$-+3(44
-2 5"3#$53($- '
(2 ' %34%#3,$(3,"5
,2
)
+* "",3($"3$"#42 535#43(%53($%
+2 5,3",$3+## "#,3-4-3(%5
52 %-+3-,+ ($53+#5
.)* )43$#$3"%"3#5$* 53-,,3"("3"+,
.) $"* )4(-3#%43,,4* "3,%(3,%53"(+
.)*) $%3$-* ),3%-43$5-3-"-* ,3+%#3,$%3#"+
Income statement
Income statement
The12thperiod:2011.1.1-2011.12.31
The 11thperiod: 2010.1.1-2010.12.31
Celltrion GSC Unit: KRW
Accounting The 12thperiod The 11thperiod
I Revenue (note 12)
-
7/24/2019 Celltrion GSC 2011 AR
75/165
dart.fss.or.kr Page 33
I.Revenue (note 12)27,824,376,329 18,964,664,043
.Cost of sales note 16 25 818 905 015 16 963 692 158
.Gross profits 2,005,471,314 2,000,971,885
.Selling and administrationex enses note 15
1,102,051,643 831,560,463
.Operating income 903,419,671 1,169,411,422
.Other income 11,129,773,751 20,754,950,919
1.Interest income note 152,899,655,527 1,855,549,359
1. Dividends 800,303,475
2. Earnings from Foreignexchange trading
82,549,962 36,351,195
3. Earnings from conversion offoreign currency
8,749,315 59
5.Reversal of bad debt provision - 47,145,960
6. Income from disposal ofavailable-for-sale securities (note 4)
6,295,403,556 8,530,332,119
7.Income from transaction ofderivative commodity (Note8)
762,477,395 8,700,424,873
8. Income from derivative
commodity (note 8)
- 1,377,588,940
8. Other income 41,442 3,297
.Non-operating expenditures 19,134,425,513 12,458,110,055
1.Interest expenses 8,599,786,747 8,456,590,896
1. Losses from Foreign exchange 212,789,229 59,760,605
2. Losses from conversion offorei n currenc
168,122 4,148,577
3. Other bad debt and 92,019,514 -
4. Loss of evaluation of Option - 3,730,615,629
6. Loss of evaluation of derivatioecommodit note 8
226,512,120
7.Impairment of available-for-salesecurities
9,907,539,513
8. Commission fees 96,261,800 206,474,539
9. Other loss348,468 519,809
.Less:profit/loss before income (7,101,232,091) 9,466,252,286
.Income tax ex ense note 12 754,037,667 2,635,639,258
.Net income (loss) (note 13,14) (6,347,194,424) 6,830,613,028
#
12 2011 1 1 2011 12 31 11 2010 1 1 2010 12
31
) & *
-
7/24/2019 Celltrion GSC 2011 AR
76/165
dart.fss.or.kr Page 34
)& *
"#$#2#$2#$)
*
+3,,$35##3### (543%%%344" )$5-3,%%344#* $#%3,,-35%-3-
+$
)-3"$#3,"#34%
+*
$#+3($+35$%34
-(
' ' ' ' ,3+%#3,$%3#"+ ,3+%#3,$%3#"+
' ' ' $-434"(3%%"3%
$+
' $-434"(3%%"3%
$+
"#$#2$"2%$ +3,,$35##3### (543%%%344" )$5-3,%%344#* "($3%5#3",,34
55
"3,$5355"3"5# ",%3#4-3+(53#
5$
"#$$2#$2#$)
*
+3,,$35##3### (543%%%344" )$5-3,%%344#* "($3%5#3",,34
55
"3,$5355"3"5# ",%3#4-3+(53#
5$
' ' ,-3-+53(5# ' ),-3-+53(5#* '
' ' ' ' ),3%-43$5-3-"
-*
),3%-43$5-3-"
-*
' ' ' $#3%453("(3%+
(
' $#3%453("(3%+
(
"#$$2$"2%$ +3,,$35##3### (543%%%344" )$%#3$--3$+#* ",$34,5345"3$
+-
)%345$3,5$34"
-*
",43$#43$5#3#
("
Statement of changes in equity
Statement of changes in equityThe 12thperiod: 2011.1.12011.12.31
The 11thperiod: 2010.1.12010.12.31
Celltrion GSC Unit: KRW
-
7/24/2019 Celltrion GSC 2011 AR
77/165
dart.fss.or.kr Page 35
Celltrion GSC Unit: KRW
Accounting CapitalCapital reserves
Adjustment of
capital
Other
comprehensiveTotal
2010.01.01
(reported
amounts)
8,661,900,000 597,333,772 (194,633,770) 103,664,934,481 (4,210,620,738) 108,518,913,7
45
Net income in this
period
- - - - 6,830,613,028 6,830,613,028
Income from
the evaluation
of available-for-
sale securities
- - - 147,725,332,318 - 147,725,332,3
18
2010.12.31 8,661,900,000 597,333,772 (194,633,770) 251,390,266,799 263,074,859,0
91
2011.01.01(report
ed amounts)
8,661,900,000 597,333,772 (194,633,770) 251,390,266,799 2,619,992,290 263,074,859,0
91
Corporate bondsdiscounts
- - 64,489,590 - (64,489,590) -
Net income in thisperiod
- - - - (6,347,194,424)
(6,347,194,424)
Income from
the evaluation
of available-for-
sale securities
- - - 10,379,525,38
5
- 10,379,525,38
5
2011.12.31 8,661,900,000 597,333,772 (130,144,180) 261,769,792,1
84
(3,791,691,724
)
267,107,190,0
52
#
$" "#$$ $ $ "#$$ $" %$ $$ "#$#
$ $ "#$# $" %$
)& *
-
7/24/2019 Celltrion GSC 2011 AR
78/165
dart.fss.or.kr Page 36
$$ )* $# )*
. "35$-3$$-3,%5 -3,453,4"34"+
$2)* ),3%-43$5-3-"-* ,3+%#3,$%3#"+
"2 $(3+($3#443$"+ 53-$(3"-$344(
2 "%3+4(3-+# '
2 43-,"3-,5 -3+(-344,
2 -$#3### %$#3###
2 "-"3+## "-"3+##
2 (3(5-3#$(3"%" (3,453"$+3(4#
2 5$3#$53($- '
Cash flow statement
Cash flow statement
The 12thperiod: 2011.1.12011.12.31
The 11thperiod: 2010.1.12010.12.31
-
7/24/2019 Celltrion GSC 2011 AR
79/165
dart.fss.or.kr Page 37
Celltrion GSC Unit: KRW
accounting The 11thperiod The 10thperiod
Cash flows from operating activities 2,914,114,639
4,679,672,728
1. Net income in this period (6,347,194,424) 6,830,613,028
2. Total non-cash expenses 15,851,077,128 9,415,241,775
1.Retirement pay 23,875,480 -
2.provision for bad debt 7,462,469 4,854,776
3.Depreciation expense 410,000 310,000
4.Amortization 242,800 242,800
5.Interest cost 5,594,015,232 5,679,218,570
6. Other provision for bad debt 91,019,514 -
2 ' %34%#3,$(3,"5
2 "",3($"3$"#
2 535#43(%53($%
%2 ),3"5(3-#%3((,* )$-3#-(35$$3%""
*
-
7/24/2019 Celltrion GSC 2011 AR
80/165
2
' -43$-(35,#
2 ,3"5(3-#%3((, +3(%#3%%"3$$5
2 ' -3#5#3+--3%#%
2 ' $3%443(++35-#
-2 )"5-3%,-3(#5* "3-4534"53"-4
2 )4-,3"-,35$#* )-+(3-443("#*
2 )* $34+$3+$435+( )$3,-43"#-3%#,*
2 )* -3#5(3($+3+%% )%3+5,35$#*
2 )* $3+"+354"3((# )%34+43%543%,4*
2 ' "$3,--3%+-
2 $3$+#345#3("# '
2 )* )$$(3%((3"4"* +-3##-3($#
2 )* )"3,%53"%"35,(* )$3(",3%(%3-%4*
2 )* )45+3$4%3+54* ,3%"-3+5$
2 ' "#"3,"-
2 45+3(#+34%, 4$,3%4-3(45
2 $#-3,-53$(# $4%3,,53,54
2 )* )"%,3-#(3"-%* (-#3"+%3554
2 )* $434--3-5# ),,3,(#*
2 )* )(,354+3$,-* "+$3#+$3$"$
2 )* )"34%-3%-$3$%"* -3+4#35#%3"#%
2 )* )"34#53,%#35(+* "34#53,%#35(+
2 %,3"+"34$5 (",3##(3-4%
2 )$#"3"+-35($* '
. )+3%443,5-3%+4* (34%$3%4-35("
$2 -+3+++3+#+3"-% $+3-#43+"53",4
2 -,3%+$3(%%3"-% 535#43+%43",4
2 "3-5535,#3### +3-55355"3###
2 43%$(3### '
"2 )(43",,3(#"3,%#
*
)$"3,4,3-(-3%$(
*
2 (43",(3%#"3,%# "3,4,3-(-3%$(
7.Loss of the option evaluation - 3,730,615,629
8.Loss of the evaluation of derivative commodities 226,512,120
9.Impairment loss of avabliable-for-sale securities 9,907,539,513
3. Non-cash income (6,295,403,556)(14,045,911,322)
1.Reversal of bad debt provision - 47,145,960
-
7/24/2019 Celltrion GSC 2011 AR
81/165
p , ,
2.Income of avabliable-for-sales securities6,295,403,556 8,530,332,119
3.Income of derivative commodity-
4,090,844,303
4. Income of the evaluation of derivative commodity-
1,377,588,940
4.Changes in assets and liabilities through operatingactivities
(294,364,509) 2,479,729,247
1.Increase in accounts receivable (746,246,910) (485,477,520)
2. Increase(decrease) in uncollected income1,781,817,985 (1,647,204,306)
3.Decrease(increase) in accounts receivable
4,095,518,833 (3,896,910)4.Decrease(increase) in advance payment1,828,972,550 (3,787,397,367)
5.Decrease(increase) in prepaid expense- 21,644,384
6.Decrease(increase) in derivative commodity 1,180,790,520-
7.Decrease(increase) in tax refund (115,355,272) 84,004,510
8.decrease(increase) in liquid deferred tax assets(2,639,232,965) (1,526,353,437)
9.Decrease(increase) in goods (798,173,897) 6,324,891
10.Decrease(increase) in goods receivable-
202,624
11.Increase(decrease) in accounts payable798,508,736 716,374,579
12.Increase in accrued expenses 104,649,150 173,669,697
13.Increase(decrease) in advanced additional t ax(236,405,243) 540,283,997
14.Decrease(increase) in deposit received 17,744,490 (66,650)
1. Increase(decrease) in accounts payable (56,978,164) 281,081,121
2.Increase(decrease) in deposit received (2,734,341,132) 4,870,903,203
3.Increase(decrease) in withholding tax (2,709,630,958) 2,709,630,958
4.Increase in non-liquid deferred tax liability 36,282,719 526,005,473
5.Increase in retirement assets (102,284,951) -
. Cash flows from investing activities (8,377,694,38
5,731,374,952
Cash received from disposal of investment 48,888,808,243 18,407,829,267
1.Decrease in short-term investment assets 46,381,533,243 9,907,837,267
2.The dispose of available-for-sale securities2,499,960,000 8,499,992,000
3.Decrease in cash deposit7,315,000 -
1.Cash received from disposal of investment (57,266,502,630) (12,676,454,315
3.Increase in short-term investment assets 57,265,302,630 2,676,454,315
2 ' $#3###3###3###
2 $3"##3### '
. %3###3###3### -##3###3###
$2 $-3###3###3### $"3,##3###3###
2 $-3###3###3### $"3,##3###3###
-
7/24/2019 Celltrion GSC 2011 AR
82/165
"2
)$$3###3###3###*
)$"3"##3###3###*
2 $$3###3###3### (3"##3###3###
2 ' 43###3###3###
.))(++) )"3-,%3(4534-+* $#3+$$3#-43,+#
. $$3$553((#3,5+ %++3(#%3#$+
. +34%(354#35(# $$3$553((#3,5+
4.The purchase of available-for-sale - 10,000,000,000
5.The purchase of consumption goods 1,200,000 -
.Cash flows from financing activities 3,000,000,000 400,000,000
-
7/24/2019 Celltrion GSC 2011 AR
83/165
1. Cash received from financing activities 14,000,000,000 12,600,000,000
1. Increase in short-term loans 14,000,000,000 12,600,000,000
2. Cash outflows from financing activities (11,000,000,000)
(12,200,000,000
)
1. Repayment of Short-term loans 11,000,000,000 5,200,000,000
2. Repayment of liquid long-term
loans
- 7,000,000,000
.Increase(decrease) of cash (I+II+III) (2,463,579,748) 10,811,047,680
.Cash at the beginning of period 11,199,550,698
388,503,018
.Cash at the end of period 8,735,970,950
11,199,550,698